Cargando…

Virtual Care during the COVID-19 Pandemic Among Patients with Hematologic Malignancies - a Princess Margaret Cancer Centre Experience

Background: The use of virtual care rapidly increased during the COVID-19 pandemic to provide adequate care for patients while minimizing contact. Studies in solid tumors show high rates of patient satisfaction with virtual care as well as cost-savings. However, little is known about the application...

Descripción completa

Detalles Bibliográficos
Autores principales:	Suleman, Adam, Vijenthira, Abi, Trong, Tran, Berlin, Alejandro, Prica, Anca, Rodin, Danielle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology. Published by Elsevier Inc. 2021
Materias:	902.Health Services Research-Lymphoid Malignancies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701830/ http://dx.doi.org/10.1182/blood-2021-149788

Ejemplares similares

The Use of Virtual Care in Patients with Hematologic Malignancies: A Scoping Review
por: Suleman, Adam, et al.
Publicado: (2022)

Impact of the COVID-19 Pandemic on Primary Care Access for Patients with Hematologic Malignancies
por: Ling, Ying, et al.
Publicado: (2021)

Impact of the COVID-19 Pandemic on in-Person Visit Rates Among Patients with Hematologic Malignancies in the United States
por: Goyal, Gaurav, et al.
Publicado: (2021)

Outcomes of Adult and Pediatric Patients with Hematologic Malignancies and COVID-19: A Systematic Review and Meta-Analysis of 1847 Patients
por: Vijenthira, Abi, et al.
Publicado: (2020)

A Prospective Survey to Understand the Preferences and Perspectives of Patients with Hematological Malignancies in a Tertiary Cancer Care Setting in India (CANCOV SURVEY)
por: Sharma, Dr. Neha, et al.
Publicado: (2021)

COVID-19 Incidence in Asymptomatic Cancer Patients Undergoing Chemotherapy
por: Monteiro, Claudia, et al.
Publicado: (2021)

Online Patient-Reported Platform Detects Trend of Increased COVID-19 Risk and Severity for Multiple Myeloma Patients on Active Lenalidomide-Based Therapy
por: Liu, Emily I., et al.
Publicado: (2021)

COVID-19 Vaccine Response in Patients with Hematologic Malignancy: A Systematic Review and Meta-Analysis
por: Gong, Inna, et al.
Publicado: (2021)

Mobile-Health Tool to Improve Care of Patients with Hematological Malignancies
por: Sanyal, Amit, et al.
Publicado: (2020)

Outcomes in Patients with Hematological Malignancies Receiving Anti-CD20 Therapy in the Setting of COVID-19 Infection
por: Lopez, Carlos A, et al.
Publicado: (2020)

The Feasibility of Virtual Toxicity Assessments in Lymphoma Patients Receiving Immunochemotherapy
por: Runge, John S., et al.
Publicado: (2020)

A Shared Electronic Health Record in a Rural Setting Maintains Hematological Cancer Services Remotely during the COVID-19 Pandemic
por: Cashman, Helen, et al.
Publicado: (2020)

FREQUÊNCI33DE COVID-19 ENTRE PORTADORES DE NEOPLASIAS HEMATOLÓGICAS: RESULTADOS DE PROGRAMA DE TRIAGEM AMPLA NO DECORRER DA PANDEMIA
por: Garnica, M., et al.
Publicado: (2020)

FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience
por: Chllamma, Muralidharan K, et al.
Publicado: (2016)

Lung cancer in never smokers from the Princess Margaret Cancer Centre
por: Korpanty, Grzegorz J., et al.
Publicado: (2018)

Neutralizing monoclonal antibodies for early treatment of hospital‐acquired SARS‐CoV‐2 infection in hematologic patients
por: Bussini, Linda, et al.
Publicado: (2022)

Worldwide Examination of Patients with CLL Hospitalized for COVID-19
por: Roeker, Lindsey E, et al.
Publicado: (2020)

Pivoting the Provision of Smoking Cessation Education in a Virtual Clinical World: The Princess Margaret Cancer Centre Experience
por: Quartey, Naa Kwarley, et al.
Publicado: (2021)

A Large London District General Hospital Highlights CLL and Bame As Risk Factors for Severe Disease Amongst Haematology-Oncology Patients
por: Farmer, Isabel, et al.
Publicado: (2020)

Prospective Pilot Study of Telehealth As Domiciliary Follow-up after Hematopoietic Cell Transplantation during the COVID19 Pandemic
por: Mussetti, Alberto, et al.
Publicado: (2020)

Reduction in Transplantation Activity without Impairment in Outcomes in the Covid-19 Era- Data from the Sarah Cannon Blood Cancer Network (SCBCN)
por: Battiwalla, Minoo, et al.
Publicado: (2020)

Management of Indian Haematology Patients during COVID19 Crisis
por: Subash, Chezhian, et al.
Publicado: (2020)

Treating Acute Leukemia during the COVID-19 Pandemic: A Multicenter Latin American Registry
por: Demichelis, Roberta, et al.
Publicado: (2020)

Ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone in patients with previously untreated non‐germinal centre B‐cell‐like diffuse large B‐cell lymphoma: A Chinese subgroup analysis of the phase III PHOENIX trial
por: Zhu, Jun, et al.
Publicado: (2022)

Impact of the COVID-19 Pandemic on the Wellbeing of International Oncology and Hematology Fellows at the Princess Margaret Cancer Center (PMCC)
por: Stecca, Carlos E., et al.
Publicado: (2022)

Association of Race, Ethnicity, Age and Socioeconomic Status with Access to Virtual Visits within the Brigham & Women's Hospital Division of Hematology during the COVID-19 Pandemic
por: Kwarteng-Siaw, Miriam, et al.
Publicado: (2021)

Pevonedistat, a NEDD8‐activating enzyme inhibitor, induces apoptosis and augments efficacy of chemotherapy and small molecule inhibitors in pre‐clinical models of diffuse large B‐cell lymphoma
por: Torka, Pallawi, et al.
Publicado: (2020)

Favourable outcomes for high‐risk Burkitt lymphoma patients (IPI 3‐5) treated with rituximab plus CODOX‐M/IVAC: Results of a phase 2 UK NCRI trial
por: Phillips, Elizabeth H., et al.
Publicado: (2020)

Plasma thymus and activation‐regulated chemokine (TARC) as diagnostic marker in pediatric Hodgkin lymphoma
por: Zijtregtop, Eline A. M., et al.
Publicado: (2020)

Genetic aberrations of NLRC5 are associated with downregulated MHC‐I antigen presentation and impaired T‐cell immunity in follicular lymphoma
por: Gunawardana, Jay, et al.
Publicado: (2020)

Longitudinal health‐related quality of life in first‐line treated patients with chronic lymphocytic leukemia: Results from the Connect(®) CLL Registry
por: Sharman, Jeff P., et al.
Publicado: (2020)

Clinical features of anthracycline‐induced cardiotoxicity in patients with malignant lymphoma who received a CHOP regimen with or without rituximab: A single‐center, retrospective observational study
por: Nakayama, Takafumi, et al.
Publicado: (2020)

Immune reconstitution in children following chemotherapy for acute leukemia
por: Williams, Anthony P., et al.
Publicado: (2020)

The contribution of human papilloma virus infection to cutaneous squamous cell carcinoma in patients with chronic lymphocytic leukemia
por: Bhavsar‐Bhakta, Preeya, et al.
Publicado: (2021)

Phase Ib study of combinations of avadomide (CC‐122), CC‐223, CC‐292, and rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma
por: Ribrag, Vincent, et al.
Publicado: (2022)

Phase II study of dose‐adjusted gemcitabine, dexamethasone, cisplatin, and rituximab in elderly relapsed diffuse large B‐cell lymphoma patients
por: Yamasaki, Satoshi, et al.
Publicado: (2020)

Mast cell density and its clinical relevance in Waldenström's macroglobulinemia
por: Lemal, Richard, et al.
Publicado: (2022)

Prevalence and the impact of hypogammaglobulinemia in newly diagnosed chronic lymphocytic lymphoma patients
por: Singh, Namrata, et al.
Publicado: (2020)

First‐line treatment of stage IIB to stage IV classical Hodgkin lymphoma in Italy, Israel, and Spain: Patient characteristics, treatment patterns, and clinical outcomes
por: Avigdor, Abraham, et al.
Publicado: (2022)

Inhibition of cyclin‐dependent kinase 9 synergistically enhances venetoclax activity in mantle cell lymphoma
por: Zhao, Xiaoxian, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5e991q7tvjh0t36mdnc10l34ac